Akebia Therapeutics Inc.

Last updated September 27, 2026

Organization details

Legal name
Akebia Therapeutics Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Cambridge
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
AKBA
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001517022
EIN
20-8756903

Board of directors

Chief executives

John P. Butler · CEO and President
Dates unknown

Director election results

Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

4 of this board's directors also sit on 8 other boards. 8 are in the same sector.

Network of Akebia Therapeutics Inc.'s board connections Agios Pharmaceuticals Inc. Agios Pharmaceuticals... Protara Therapeutics Inc. Protara Therapeutics I... SCYNEXIS Inc. SCYNEXIS Inc. Spero Therapeutics Inc. Spero Therapeutics Inc... Talphera Inc. Talphera Inc. Tectonic Therapeutic Inc. Tectonic Therapeutic I... Tvardi Therapeutics Inc. Tvardi Therapeutics In... Vericel Corporation Vericel Corporation Adrian Adams Adrian Adams Cynthia Smith Cynthia Smith Philip J. Vickers Philip J. Vickers Steven C. Gilman Steven C. Gilman Akebia Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$86,588
1 purchase by 1 insider
Sold, last 12 months
$962,955
16 sales by 6 insiders
Date Insider Transaction Shares Price Value
Aug 6, 2026 John P. Butler Director, Officer (CEO and President) Option exercise +350,000 $0.63 $220,500
Jun 29, 2026 Ostrowski Erik Officer (SVP, CFO, CBO & Treasurer) Open-market sale −56,019 $1.11 $62,181
Jun 17, 2026 Myles Wolf Director Grant or award +35,700 — —
Jun 17, 2026 Cynthia Smith Director Grant or award +35,700 — —
Jun 17, 2026 Michael W. Rogers Director Grant or award +35,700 — —
Jun 17, 2026 Ron Frieson Director Grant or award +35,700 — —
Jun 17, 2026 Leanne M. Zumwalt Director Grant or award +35,700 — —
Jun 17, 2026 Adrian Adams Director Grant or award +35,700 — —
Mar 4, 2026 John P. Butler Director, Officer (CEO and President) Open-market purchase +69,270 $1.25 $86,588
Feb 2, 2026 Malabre Richard C Officer (SVP, Chief Accounting Officer) Open-market sale −36,142 $1.39 $50,237
Feb 2, 2026 Grund Nicholas Officer (Chief Commercial Officer) Open-market sale −53,585 $1.39 $74,483
Feb 2, 2026 Burke Steven Keith Officer (SVP, Chief Medical Officer) Open-market sale −21,582 $1.39 $29,999
Feb 2, 2026 Rucci Carolyn M. Officer (SVP, Chief Legal Officer) Open-market sale −16,846 $1.39 $23,416
Feb 2, 2026 Ostrowski Erik Officer (SVP, CFO, CBO & Treasurer) Open-market sale −34,951 $1.39 $48,582
Feb 2, 2026 John P. Butler Director, Officer (CEO and President) Open-market sale −46,660 $1.39 $64,857

Organizations in the same sector, closest in location and size first.

Questions about Akebia Therapeutics Inc.

Who is the CEO of Akebia Therapeutics Inc.?

John P. Butler is Akebia Therapeutics Inc.'s CEO and President.

How many directors are on Akebia Therapeutics Inc.'s board?

Akebia Therapeutics Inc.'s board has 9 directors: Adrian Adams, Cynthia Smith, John P. Butler, Leanne M. Zumwalt, Michael W. Rogers, Myles Wolf, Philip J. Vickers, Ron Frieson and Steven C. Gilman.

Are Akebia Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Akebia Therapeutics Inc. insiders bought $86,588 of shares in 1 purchase and sold $962,955 of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="akebia-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.